GB Sciences, Inc. (GBLX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.75 Million USD | 26.02% |
| 2022 | 1.39 Million USD | 0.81% |
| 2021 | 1.38 Million USD | -68.93% |
| 2020 | 4.45 Million USD | -52.67% |
| 2019 | 9.41 Million USD | 8.42% |
| 2018 | 8.68 Million USD | 14.97% |
| 2017 | 7.55 Million USD | 92.25% |
| 2016 | 3.92 Million USD | 50.43% |
| 2015 | 2.61 Million USD | 8606.96% |
| 2014 | 30 Thousand USD | -97.63% |
| 2013 | 1.26 Million USD | 89.17% |
| 2012 | 670 Thousand USD | -10.67% |
| 2011 | 750 Thousand USD | -15.73% |
| 2010 | 890 Thousand USD | 28.99% |
| 2009 | 690 Thousand USD | 133.9% |
| 2008 | 295 Thousand USD | 7275.0% |
| 2007 | 4000.00 USD | -97.98% |
| 2006 | 197.74 Thousand USD | 31.39% |
| 2005 | 150.5 Thousand USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 20 Thousand USD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q4 | 1.75 Million USD | 16.33% |
| 2023 FY | 1.75 Million USD | 26.02% |
| 2023 Q2 | 1.5 Million USD | 4.56% |
| 2023 Q3 | 1.51 Million USD | 0.71% |
| 2023 Q1 | 1.43 Million USD | 2.87% |
| 2022 Q3 | 1.39 Million USD | 0.41% |
| 2022 Q1 | 1.38 Million USD | 0.22% |
| 2022 Q4 | 1.39 Million USD | 0.06% |
| 2022 Q2 | 1.38 Million USD | 0.11% |
| 2022 FY | 1.39 Million USD | 0.81% |
| 2021 Q1 | 4 Million USD | -10.03% |
| 2021 FY | 1.38 Million USD | -68.93% |
| 2021 Q4 | 1.38 Million USD | -28.14% |
| 2021 Q2 | 4.12 Million USD | 2.75% |
| 2021 Q3 | 1.92 Million USD | -53.23% |
| 2020 Q2 | 9.89 Million USD | -8.94% |
| 2020 Q4 | 4.45 Million USD | 2.65% |
| 2020 FY | 4.45 Million USD | -52.67% |
| 2020 Q1 | 10.86 Million USD | 15.39% |
| 2020 Q3 | 4.34 Million USD | -56.11% |
| 2019 Q2 | 8.84 Million USD | -21.17% |
| 2019 Q1 | 11.22 Million USD | 29.2% |
| 2019 Q3 | 9.19 Million USD | 3.98% |
| 2019 Q4 | 9.41 Million USD | 2.37% |
| 2019 FY | 9.41 Million USD | 8.42% |
| 2018 Q2 | 7.49 Million USD | -1.87% |
| 2018 FY | 8.68 Million USD | 14.97% |
| 2018 Q4 | 8.68 Million USD | 12.31% |
| 2018 Q3 | 7.73 Million USD | 3.22% |
| 2018 Q1 | 7.63 Million USD | 1.06% |
| 2017 Q2 | 6.71 Million USD | 69.86% |
| 2017 Q1 | 3.95 Million USD | 0.59% |
| 2017 FY | 7.55 Million USD | 92.25% |
| 2017 Q4 | 7.55 Million USD | 4.33% |
| 2017 Q3 | 7.24 Million USD | 7.85% |
| 2016 Q2 | 6.7 Million USD | 166.08% |
| 2016 FY | 3.92 Million USD | 50.43% |
| 2016 Q1 | 2.52 Million USD | -3.52% |
| 2016 Q4 | 3.92 Million USD | -18.85% |
| 2016 Q3 | 4.84 Million USD | -27.79% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | 2.61 Million USD | 21.85% |
| 2015 Q2 | 1.58 Million USD | 0.0% |
| 2015 Q3 | 2.14 Million USD | 34.92% |
| 2015 FY | 2.61 Million USD | 8606.96% |
| 2014 Q1 | 373.61 Thousand USD | -70.52% |
| 2014 FY | 30 Thousand USD | -97.63% |
| 2014 Q4 | 30 Thousand USD | 500.0% |
| 2014 Q3 | 5000.00 USD | 0.0% |
| 2014 Q2 | 5000.00 USD | -98.66% |
| 2013 Q1 | 685.11 Thousand USD | 2.26% |
| 2013 Q3 | 624.77 Thousand USD | 13.76% |
| 2013 Q2 | 549.2 Thousand USD | -19.84% |
| 2013 Q4 | 1.26 Million USD | 102.86% |
| 2013 FY | 1.26 Million USD | 89.17% |
| 2012 Q3 | 546 Thousand USD | -8.57% |
| 2012 Q1 | 584.59 Thousand USD | -22.05% |
| 2012 Q2 | 597.16 Thousand USD | 2.15% |
| 2012 Q4 | 670 Thousand USD | 22.71% |
| 2012 FY | 670 Thousand USD | -10.67% |
| 2011 Q4 | 750 Thousand USD | -23.42% |
| 2011 Q2 | 979.35 Thousand USD | -5.09% |
| 2011 Q3 | 979.35 Thousand USD | 0.0% |
| 2011 FY | 750 Thousand USD | -15.73% |
| 2011 Q1 | 1.03 Million USD | 15.95% |
| 2010 FY | 890 Thousand USD | 28.99% |
| 2010 Q4 | 890 Thousand USD | -5.81% |
| 2010 Q1 | 890.68 Thousand USD | 29.09% |
| 2010 Q2 | 951.99 Thousand USD | 6.88% |
| 2010 Q3 | 944.9 Thousand USD | -0.74% |
| 2009 Q4 | 690 Thousand USD | 15.7% |
| 2009 FY | 690 Thousand USD | 133.9% |
| 2009 Q3 | 596.37 Thousand USD | 57.33% |
| 2009 Q2 | 379.05 Thousand USD | 21.1% |
| 2009 Q1 | 313 Thousand USD | 6.1% |
| 2008 Q3 | 256.5 Thousand USD | 6.65% |
| 2008 Q4 | 295 Thousand USD | 15.01% |
| 2008 Q1 | 4000.00 USD | 0.0% |
| 2008 Q2 | 240.5 Thousand USD | 5912.5% |
| 2008 FY | 295 Thousand USD | 7275.0% |
| 2007 FY | 4000.00 USD | -97.98% |
| 2007 Q4 | 4000.00 USD | -97.23% |
| 2007 Q3 | 144.5 Thousand USD | -13.96% |
| 2007 Q2 | 167.95 Thousand USD | 0.0% |
| 2007 Q1 | - USD | -100.0% |
| 2006 Q2 | 265.05 Thousand USD | 76.12% |
| 2006 Q3 | 306.46 Thousand USD | 15.62% |
| 2006 FY | 197.74 Thousand USD | 31.39% |
| 2006 Q4 | 197.74 Thousand USD | -35.48% |
| 2006 Q1 | 150.5 Thousand USD | 0.0% |
| 2005 Q4 | 150.5 Thousand USD | 0.0% |
| 2005 Q3 | 150.5 Thousand USD | 0.0% |
| 2005 FY | 150.5 Thousand USD | 0.0% |
| 2005 Q2 | - USD | -100.0% |
| 2005 Q1 | 80 Thousand USD | 0.0% |
| 2004 Q1 | 45 Thousand USD | 125.0% |
| 2004 Q4 | - USD | -100.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q2 | 195 Thousand USD | 333.33% |
| 2004 Q3 | 320.37 Thousand USD | 64.3% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | 20 Thousand USD | 0.0% |
| 2003 FY | 20 Thousand USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 94.09% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -179.221% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1336.169% |
| Qrons Inc. | 351.84 Thousand USD | -400.02% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -132.65% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 95.944% |
| BioStem Technologies, Inc. | 4.71 Million USD | 62.659% |
| Skye Bioscience, Inc. | 4.61 Million USD | 61.881% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | 310 Thousand USD | -467.518% |
| CSL Limited | 12.18 Billion USD | 99.986% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 96.138% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 91.345% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -6740.495% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 70.034% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 95.73% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 57.319% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -337.803% |
| SQZ Biotechnologies Company | 27.47 Million USD | 93.596% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 24.362% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -85.528% |
| Mesoblast Limited | 118.7 Million USD | 98.518% |
| Marizyme, Inc. | 18.71 Million USD | 90.601% |
| Genus plc | 233.1 Million USD | 99.245% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 39.963% |
| Pharming Group N.V. | 171.54 Million USD | 98.974% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -98.106% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -30.941% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -134.574% |
| ContraFect Corporation | 2.88 Million USD | 38.934% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1198.506% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -21.64% |
| IMV Inc. | 28.88 Million USD | 93.909% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 68.908% |
| MultiCell Technologies, Inc. | 202.58 USD | -868350.489% |
| ONE Bio Corp. | 19.71 Million USD | 91.076% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 96.94% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -17.699% |
| Q BioMed Inc. | 4.1 Million USD | 57.194% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 94.685% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -43.224% |
| Biomind Labs Inc. | 735.54 Thousand USD | -139.185% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 97.399% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 41.864% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 86.464% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -389.09% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1143.168% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 22.099% |
| Alpha Cognition Inc. | 1.22 Million USD | -44.162% |
| HST Global, Inc. | 98.31 Thousand USD | -1689.387% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -607.344% |
| Halberd Corporation | 150 Thousand USD | -1072.871% |
| Enzolytics Inc. | 996.33 Thousand USD | -76.577% |
| Agentix Corp. | 50 Thousand USD | -3418.614% |
| Resverlogix Corp. | 6.49 Million USD | 72.896% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -588.326% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 91.203% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 75.126% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 35.05% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -17105.936% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.579% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -776.952% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 26.626% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -667.281% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1083.491% |
| Kadimastem Ltd | 891.22 Thousand USD | -97.403% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -603.211% |
| LadRx Corporation | 33.6 Thousand USD | -5135.098% |
| Cell Source, Inc. | 9.25 Million USD | 80.989% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -132.65% |
| NovAccess Global Inc. | 2.19 Million USD | 20.027% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -670.352% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -733.894% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 64.694% |
| Mobile Lads Corp. | 484.28 Thousand USD | -263.28% |
| CytoDyn Inc. | 30.07 Million USD | 94.15% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 77.502% |
| SYBLEU INC | 477.5 Thousand USD | -268.441% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 62.847% |
| International Stem Cell Corporation | 4.17 Million USD | 57.891% |
| Bioxytran, Inc. | 1.92 Million USD | 8.607% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2718.815% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 19.331% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 78.844% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 79.507% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -13.104% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -556.458% |
| Neutra Corp. | 54.15 Thousand USD | -3148.591% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 3.863% |
| PureTech Health plc | 25.51 Million USD | 93.104% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -43.708% |
| IXICO plc | 472.02 Thousand USD | -272.716% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 88.65% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 97.174% |
| CSL Limited | 12.18 Billion USD | 99.986% |
| Cellectis S.A. | 92.77 Million USD | 98.104% |